Доказательная база применения препаратов альфа-интерферонов при ОРВИ

Currently, the clinical efficacy of recombinant alpha-interferon preparations in acute respiratory viral infections (ARVI) is a subject for intense discussion among medical specialists. We have analyzed the published results of clinical trials defined by satisfactory methodological quality and devoted to assessing the clinical efficacy and safety of alpha-interferon preparations for local administration in ARVI and, in particular, in COVID-19. It was showed that these drugs administered intranasally can be effective in post-exposure ARVI prevention (primarily the rhinovirus infection, to a lesser extent – other ARVI, including seasonal influenza). Besides, intranasal administration of IFN-α2 facilitates the course of ARVI cases following such prevention. The prophylactic and therapeutic efficacy of interferon preparations in COVID-19 is possible, but needs further confirmation in clinical trials. At the same time, the local use of IFN-α2 preparations for the prevention and treatment of ARVI is sufficiently safe for patients.